Clinical Trial Update: A Study of BMS-863233 in Patients With Hematologic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Bristol-Myers Squibb's BMS-863233 in patients with refractory hematologic cancer. The Phase 1/2 study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• BMS-863233

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Refractory Hematologic Cancer | Phase 1, Phase 2 | Status: TERMINATED